Relative Abundance of apoE and Aβ1–42 Associated with Abnormal Prion Protein Differs between Creutzfeldt-Jakob Disease Subtypes

详细信息    查看全文

• 作者：Roger A. Moore ; Young Pyo Choi ; Mark W. Head ; James W. Ironside ; Robert Faris ; Diane L. Ritchie ; Gianluigi Zanusso ; Suzette A. Priola
• 刊名：Journal of Proteome Research
• 出版年：2016
• 出版时间：December 2, 2016
• 年：2016
• 卷：15
• 期：12
• 页码：4518-4531
• 全文大小：655K
• ISSN：1535-3907

文摘

Aggregated and protease-resistant mammalian prion protein (PrP^Sc) is the primary protein component of infectious prions. Enriched PrP^Sc preparations are often used to study the mechanisms that underly prion disease. However, most enrichment procedures are relatively nonspecific and tend to yield significant amounts of non-PrP^Sc components including various proteins that could confound functional and structural studies. It is thus important to identify these proteins and assess their potential relevance to prion pathogenesis. Following proteinase K treatment and phosphotungstic acid precipitation of brain homogenate, we have used mass spectrometry to analyze the protein content of PrP^Sc isolated from prion-infected mice, multiple cases of sporadic Creutzfeldt-Jakob disease (sCJD), and human growth hormone associated cases of iatrogenic CJD (iCJD). Creatine kinase was the primary protein contaminant in all PrP^Sc samples, while many of the other proteins identified were also found in non-CJD controls, which suggests that they are not CJD specific. Interestingly, the Alzheimer’s disease associated peptide amyloid β 1–42 (Aβ1–42) was identified in the majority of the sCJD cases as well as non-CJD age-matched controls, while apoliprotein E was found in greater abundance in the sCJD cases. By contrast, while some of the iCJD cases showed evidence of higher molecular weight Aβ oligomers, monomeric Aβ1–42 peptide was not detected by immunoblot, and only one case had significant levels of apolipoprotein E. Our data are consistent with the age-associated deposition of Aβ1–42 in older sporadic CJD and non-CJD patients and suggest that both apolipoprotein E and Aβ1–42 abundance can differ depending upon the type of CJD.